Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
33,533,099
-
Shares change
-
+707,041
-
Total reported value, excl. options
-
$816,251,800
-
Value change
-
+$17,173,667
-
Put/Call ratio
-
20.5%
-
Number of buys
-
28
-
Number of sells
-
-20
-
Price
-
$24.35
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q2 2021
69 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q2 2021.
ADC Therapeutics SA - Common Shares (ADCT) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33,533,099 shares
of 124,058,172 outstanding shares and own 27.03% of the company stock.
Largest 10 shareholders include FMR LLC (7,672,673 shares), Redmile Group, LLC (7,522,029 shares), JPMORGAN CHASE & CO (3,198,208 shares), ALLIANCEBERNSTEIN L.P. (3,053,248 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,662,585 shares), Vantage Consulting Group Inc (1,680,149 shares), Grosvenor Holdings, L.L.C. (1,517,212 shares), BAKER BROS. ADVISORS LP (1,418,107 shares), EVENTIDE ASSET MANAGEMENT, LLC (1,311,990 shares), and HHLR ADVISORS, LTD. (500,000 shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.